| 1 |
33526487 | A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis. | 2021 Mar 18 |
1 |
| 2 |
34093527 | Physiologically Relevant Concentrations of Dolutegravir, Emtricitabine, and Efavirenz Induce Distinct Metabolic Alterations in HeLa Epithelial and BV2 Microglial Cells. | 2021 |
1 |
| 3 |
30388308 | Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine. | 2019 Apr |
1 |
| 4 |
31339677 | Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. | 2019 Aug 29 |
1 |
| 5 |
28961682 | Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. | 2018 Jan 1 |
1 |
| 6 |
29368537 | Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment. | 2018 Apr |
1 |
| 7 |
29938701 | A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice. | 2018 Apr-Jun |
2 |
| 8 |
28076335 | Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate. | 2017 |
3 |
| 9 |
26892863 | Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. | 2016 Mar |
3 |
| 10 |
26952360 | The role of tenofovir alafenamide in future HIV management. | 2016 May |
4 |